ANDA 207240, held by Sciegen Pharms. Aripiprazole.
As of Nov 16, 2026, ANDA 207240 (Aripiprazole), held by Sciegen Pharms, was first approved by FDA on Apr 18, 2018, with 5 approved supplements and 0 published complete response letters.
Aripiprazole orally disintegrating tablets are indicated for the treatment of: Schizophrenia Irritability Associated with Autistic Disorder Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic. The oral formulation is indicated for: Schizophrenia Irritability Associated with Autistic Disorder Treatment of Tourette’s disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 18, 2018 | Original application | Approved | None posted |
| Aripiprazole10MG · tablet, orally disintegrating;oral | Aripiprazole | Rx |
| Aripiprazole15MG · tablet, orally disintegrating;oral | Aripiprazole | Rx |
| Jan 24, 2025 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jan 23, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jan 23, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Feb 1, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 5, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 18, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters